Nivolumab with chemotherapy improves response, survival in AML study patients
The immunotherapy drug nivolumab in combination with standard chemotherapy more than doubled response rates and improved overall survival in patients with acute myeloid leukemia (AML), according to preliminary findings of a new study.
Leave a Reply